Min Tao
Soochow University (Taiwan)
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Min Tao.
Scientific Reports | 2015
Yixiang Mao; Min Tao; Xiaoyan Jia; Hong Xu; Kai Chen; Hongwei Tang; Donghui Li
Concurrent diabetes has been linked with an increased risk of death in many cancers, but findings in pancreatic cancer have been inconsistent. We performed a systematic review and meta-analysis to assess the effect of diabetes on survival in patients with pancreatic cancer. Of 4, 463 original articles, 41 were included in the review; 29 studies with 33 risk estimates were included in the meta-analysis. In the overall comparison of patients with pancreatic cancer and diabetes with their nondiabetic counterparts, the former had significantly higher all-cause mortality (pooled HR: 1.13; 95% CI: 1.04–1.22). Subgroup analyses showed that diabetes was associated with poor survival in patients with resectable disease (HR: 1.37; 95% CI: 1.15–1.63) but not in those with unresectable disease (HR: 1.07; 95% CI: 0.89–1.29). The HR (95% CI) was 1.52 (1.20–1.93) for patients with new-onset diabetes (≤2 years of diabetes duration) and 1.22 (0.83–1.80) for those with longstanding diabetes (>2 years). Diabetes was associated with higher mortality overall in patients with pancreatic cancer. The effect of diabetes on overall survival was associated with the stages of tumor and the duration of diabetes.
Scientific Reports | 2017
Hong Jian; Wei Li; Zhiyong Ma; Jianjin Huang; Jifeng Feng; Yong Song; Beili Gao; Huili Zhu; Min Tao; Chong Bai; Shenglin Ma; Hongming Pan; Shukui Qin; Dong Hua; Yongfeng Yu; Shun Lu
Epidermal growth factor receptor tyrosine-kinase inhibitors (EGFR-TKIs) are standard treatment for advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation. However, EGFR mutation testing is not attainable in approximately 20% of patients. The current study examined intercalating and maintaining gefitinib treatment in stage IIIB/IV non-squamous NSCLC, never or former light smoking patients with unknown EGFR mutation status. Briefly, 219 patients who achieved stable disease (SD) with gemcitabine (1250 mg/m2) plus carboplatin (5 AUC) were randomized at 1:1 ratio to continue chemotherapy (n = 110) or intercalating gefitinib (250 mg/day on days 15–25 of each cycle until disease progress (n = 109). Progression-free survival (PFS) was 9.7 vs. 4.2 month in the gefitinib vs. control arm (HR: 0.41, 95% CI: 0.31–0.56; P < 0.001). Overall survival (OS) was also longer in the gefitinib arm (20.1 vs. 15.4 months; HR: 0.68; 95% CI 0.48–0.97; P = 0.0323). Adverse events, including diarrhea, dermal reaction and thrombocytopenia, were more common in the gefitinib arm. In conclusion, intercalating and maintenance gefitinib treatment is a viable option for advanced NSCLC patients with unknown EGFR mutation status in subpopulations with high EFGR mutation rate.
Investigational New Drugs | 2018
Xuenong Ouyang; Meiqi Shi; Fangwei Jie; Yuxian Bai; Peng Shen; Zhuang Yu; Xiuwen Wang; Cheng Huang; Min Tao; Zhehai Wang; Conghua Xie; Qi Wu; Yongqian Shu; Baohui Han; Fengchun Zhang; Yiping Zhang; Chunhong Hu; Xitao Ma; Yongjie Liang; Anlan Wang; Bing Lu; Yi Shi; Jinfei Chen; Zhixiang Zhuang; Wang J; Jianjin Huang; Changhui Wang; Chunxue Bai; Xin Zhou; Qiang Li
Journal of Clinical Oncology | 2017
Li Zhang; Shun Lu; Ying Cheng; Zhihuang Hu; Zhiwei Chen; G. Chen; Xiaoqing Liu; Jin-Ji Yang; Jia Chen; Meijuan Huang; Min Tao; Gang Cheng; Cheng Huang; Caicun Zhou; Weimin Zhang; Haixia Zhao
Journal of Clinical Oncology | 2018
Jin Li; Wenying Deng; Lu Wen; Junsheng Wang; Guifang Zhang; Haijun Zhong; Tongfu Jia; Jianwei Yang; Yi Ba; Yuxian Bai; Xiaoyan Lin; Mei Wang; Lin Wang; Likun Liu; Yifu He; Min Tao; Congying Xie; Feng Ye; Xiang-yuan Wu; Shukui Qin
Journal of Clinical Oncology | 2018
Wenying Deng; Shukui Qin; Jin Li; Lu Wen; Junsheng Wang; Guifang Zhang; Haijun Zhong; Jianwei Yang; Yi Ba; Yuxian Bai; Xiaoyan Lin; Mei Wang; Lin Wang; Likun Liu; Yifu He; Min Tao; Congying Xie; Feng Ye; Xiang-yuan Wu; Tongfu Jia
Journal of Clinical Oncology | 2018
Haijun Zhong; Shukui Qin; Jin Li; Wenying Deng; Lu Wen; Junsheng Wang; Guifang Zhang; Tongfu Jia; Jianwei Yang; Yi Ba; Yuxian Bai; Mei Wang; Lin Wang; Likun Liu; Yifu He; Min Tao; Congying Xie; Feng Ye; Xiang-yuan Wu; Xiaoyan Lin
Journal of Clinical Oncology | 2018
Junsheng Wang; Shukui Qin; Jin Li; Wenying Deng; Lu Wen; Guifang Zhang; Haijun Zhong; Tongfu Jia; Jianwei Yang; Yuxian Bai; Xiaoyan Lin; Mei Wang; Lin Wang; Likun Liu; Yifu He; Min Tao; Congying Xie; Feng Ye; Xiang-yuan Wu; Yi Ba
Journal of Clinical Oncology | 2018
Guifang Zhang; Shukui Qin; Jin Li; Wenying Deng; Lu Wen; Junsheng Wang; Haijun Zhong; Tongfu Jia; Jianwei Yang; Yi Ba; Xiaoyan Lin; Mei Wang; Lin Wang; Likun Liu; Yifu He; Min Tao; Congying Xie; Feng Ye; Xiang-yuan Wu; Yuxian Bai
Journal of Clinical Oncology | 2018
Lu Wen; Shukui Qin; Jin Li; Wenying Deng; Junsheng Wang; Guifang Zhang; Haijun Zhong; Tongfu Jia; Yi Ba; Yuxian Bai; Xiaoyan Lin; Mei Wang; Lin Wang; Likun Liu; Yifu He; Min Tao; Congying Xie; Feng Ye; Xiang-yuan Wu; Jianwei Yang